

Award Number: W81XWH-06-1-0767

TITLE: Pilot study on Factors Secreted by Differentiating Mammary Epithelial Cells (MECs) that Can Suppress Proliferation of Breast Cancer Cells

PRINCIPAL INVESTIGATOR: Dr. Xuning (Emily) Guo

CONTRACTING ORGANIZATION: University of California
Irvine, CA 92697

REPORT DATE: October 2007

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.				
1. REPORT DATE (DD-MM-YYYY) 01-10-2007		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 26 Sep 2006- 25 Sep 2007
4. TITLE AND SUBTITLE Pilot Study on Factors Secreted by Differentiating Mammary Epithelial Cells (MECs) that can Suppress Proliferation of Breast Cancer Cells		5a. CONTRACT NUMBER		
		5b. GRANT NUMBER W81XWH-06-1-0767		
		5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Dr. Xuning (Emily) Guo		5d. PROJECT NUMBER		
		5e. TASK NUMBER		
		5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California, Irvine Irvine, CA 92697		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S Army Medical Research and Materiel Command Fort Detrick, MD 21702-5012		10. SPONSOR/MONITOR'S ACRONYM(S)		
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				
13. SUPPLEMENTARY NOTES				
14. ABSTRACT In normal cells, proliferation and differentiation are regulated and coordinated in a way that activation of differentiation in normal cells is typically associated with cessation of proliferation. However, the balance between the two is usually disrupted in tumorigenesis, ultimately leading to a complex cellular phenotype typical of cancer cells. In attempts to identify the differentiation-inducing factors in conditioned medium, conditioned medium was fractioned and applied to breast cancer cell, MCF7, cultured in Matrigel. Unexpectedly, a cytotoxic activity was observed on MCF7 cells treated with the fraction of molecular weight between 10-50kDa after seven days. In the past year, I first confirmed the cytotoxicity on various breast cancer cell lines with different genetic backgrounds, including MD-AMB-468 and SKBR3. From mass spectrometric analysis on this 10-50kDa fraction of the conditioned medium, six factors such as interleukins (ILs), bone morphogenetic proteins (BMPs), fibroblast growth factors (FGFs) and other cytokines, which are known to be involved in cell proliferation and death, have been selected as proteins of interests and their cytotoxic activities were confirmed by immunodepletion. Chinese hamster ovary (CHO) cells overexpressing each of the six factors have been established for future reconstitution experiments and animal studies.				
15. SUBJECT TERMS No subject terms provided.				
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U		
				19a. NAME OF RESPONSIBLE PERSON USAMRMC
				19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4-7
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusion.....	7
References.....	8
Appendices.....	9

Introduction

In the United States, breast cancer is the most common cancer and second leading cause of cancer mortality in women¹⁻². Our lab is interested in studying the proliferation and differentiation of mammary epithelial cells (MEC) and developing therapies for breast cancer. In normal cells, proliferation and differentiation are regulated and coordinated in a way that activation of differentiation in normal cells is typically associated with cessation of proliferation. However, the balance between the two is usually disrupted in tumorigenesis, ultimately leading to a complex cellular phenotype typical of cancer cells³⁻⁵. Based on this premise, differentiation-inducing therapies focus on suppressing erratic proliferation by reactivating differentiation in cancer cells. Differentiation therapy is one of the tumor dormancy therapies besides apoptosis-inducing, anti-angiogenic and anti-metastasis therapies as proposed by Uhr⁶. At present, the most successful differentiation-inducing therapy is the application of all-trans-retinoic-acid (ATRA) to acute promyelocytic leukemia⁷⁻⁹. ATRA has multiple cellular targets and administration of ATRA induces terminal differentiation of arrested myeloid cells¹⁰⁻¹². Nevertheless, utilization of tumor dormancy therapy in solid tumors is underdeveloped, despite many solid tumors have been proved to be induced to differentiate *in vitro* by differentiation-inducers which either function in cell-specific or non-specific manner¹³.

However, most of these studies on solid tumors were done in two-dimension (2D) culture, which has its intrinsic limitations as over-simplifying *in vivo* microenvironment. *In vitro* 3D culture system utilizing Matrigel is a valuable technique that reproduces *in vivo* microenvironment and has been widely used in studying epithelium development *in vitro*¹⁴⁻¹⁶. In previous studies, we showed that BRCA1-depleted MECs failed to differentiate in 3D culture and exhibited numerous physiological features of breast cancer cells cultured in Matrigel, including the formation of multilobular aggregates with completely filled lumen¹⁷. We further demonstrated that formation of acinus structure can be rescued by culturing the cells with conditioned medium collected from differentiating MECs. This observation on conditioned medium suggested that certain factor(s) secreted by MECs might serve in a paracrine/autocrine fashion to suppress cell proliferation but induce cell differentiation, whereas BRCA1-depleted cells lack such activity. In attempts to identify the differentiation-inducing factors in conditioned medium, we fractionated the conditioned medium according to the molecular weight and applied each fraction to breast cancer cell, MCF7, cultured in eight-well chamber slide coated with Matrigel. We observed a cytotoxic activity in the cells treated with the fraction of molecular weight between 10-50kDa and the number of viable cells cultured with this fraction dropped to undetectable after seven days in 3D culture. On the contrary, no effect was observed on normal MECs treated with the same fraction, suggesting this fraction acts only on differentiation-defective breast cancer cells. Identification and characterization of such natural factors that specifically suppress proliferation and induce cell death of breast cancer cells will potentially provide a novel tumor dormancy therapy for treating breast cancer.

Body

RESEARCH DESIGN AND DATA

In our preliminary results, we have demonstrated that 10-50kDa fraction of the conditioned medium collected from MCF10A cells growing in Matrigel has a cytotoxic activity on MCF7 cells also growing in Matrigel. MCF10A cells themselves are not affected under the same treatment. In addition, the highest cytotoxicity is observed on the conditioned medium specifically collected on day 3 and 4 after seeding MCF10A cells in Matrigel. This finding is consistent with the time course of normal acinus formation as on day 3 and 4, MCF10A cells start to differentiate into two distinct populations: a well-polarized outer layer and a poorly-polarized inner layer which eventually die to form the hollow lumen⁴. Before go into the details of identifying cytotoxic factors in the 10-50kDa fraction, I started with repeating the cell killing assay as described for MCF7 cells on other breast cancer cell lines.

1. Test of the cytotoxic activity of the fractionated conditioned medium harvested from differentiating MCF10A on breast cancer cell lines with different genetic backgrounds.

Our preliminary data were based on MCF7 cells which were derived from a pleural effusion containing

metastatic tumor cells from a human mammary adenocarcinoma¹⁸. MCF7 cells retain several characteristics of differentiated MECs including ability to process 17 β -estradiol (E2) via cytoplasmic estrogen receptors (ERs)¹⁹⁻²⁰. Basal level of BRCA1 is high in MCF7 partially due to retardation of protein degradation²⁰. To exclude the possibility of cell type specificity, I tested the cytotoxic activity of the fractionated medium on three other breast cancer cell lines including SKBR3, HCC1937, MDA-MB-231 and MDA-MB-468, following the same experiment procedures as described for MCF7 cells. Characteristics of these cell lines in terms of disease, derived origin, malignancy and genetic backgrounds are listed below in Table 1²¹⁻²⁷. As shown in Figure 1 and 2, 10-50kDa fraction of conditioned medium had similar cytotoxic effect on SKBR3 and MDA-MB468 compared to MCF7. MDA-MB231, on the other side, failed to respond to this treatment which may be due to the malignancy of the origin of this cell line (Figure 3). HCC1937 cells were also tested but failed to grow in Matrigel (data not shown). Nevertheless, the cytotoxicity of 10-50kDa fraction of conditioned medium has been confirmed in three breast cancer cell lines with different genetic backgrounds. However, MCF7 was still used as a prototype in most of our later assays.

Table 1. Characteristics of different breast cancer cell lines in terms of origin, malignancy and genetic backgrounds.

Cell line	Disease	Origin	Malignancy	p53	Her2	BRCA1	ER
MCF7	Adenocarcinoma	pleural effusion	metastasis	+	+	+	+
SKBR3	Adenocarcinoma	pleural effusion	metastasis	MU*	+++	-	-
HCC1937	Ductal carcinoma	solid tumor	stage IIB, grade 3	-	-	MU	-
MDA-MB-231	Adenocarcinoma	pleural effusion	metastasis	MU	+	+	-
MDA-MB-468	Adenocarcinoma	pleural effusion	metastasis	MU	-	+	-

*MU, mutated




Figure1. Fractionated conditioned medium from differentiating MCF10A suppress proliferation and induce cell death in SKBR3. A) SKBR3 were fed every 12 hours with different fractions of conditioned medium. B) Viable cell numbers were calculated in term of fold of increase. a, no CDMD; b, total CDMD; c, total supernatant; d, 10-50kDa; e, <10kDa.




Figure2. Fractionated conditioned medium from differentiating MCF10A suppress proliferation and induce cell death in MDA-MB468. A) MDA-MB468 were fed every 12 hours with different fractions of conditioned medium. B) Viable cell numbers were calculated in term of fold of increase. a, no CDMD; b, total CDMD; c, total supernatant; d, 10-50kDa; e, <10kDa.




Figure3. Fractionated conditioned medium from differentiating MCF10A suppress proliferation and induce cell death in MDA-MB231. A)MDA-MB231 were fed every 12 hours with different fractions of conditioned medium. B) Viable cell numbers were calculated in term of fold of increase. a, no CDMD; b, total CDMD; c, total supernatant; d, 10-50kDa; e, <10kDa.

2. Identify the secreted factors that have cytotoxic activity on breast cancer cells.

2a) Identification the differentially secreted factors using shotgun proteomics mass spectrometry (MS). As conditioned medium collected from MCF10A cells induces cell death of different breast cancer cell lines growing in Matrigel, it is likely that factors secreted from MCF10A but not breast cancer cells have killing activity. To identify the differentially secreted proteins, I collected the conditioned media from both MCF10A and MCF7 cells cultured in Matrigel every 12 hours for a week. Fractionation was performed as described for cell killing assays and proteins in 10-50kDa fractions were precipitated by trichloric acid. Then, the protein pellets were redissolved and separated on SDS-PAGE by molecular weight. The gel was sliced every 2mm and proteins in each slice were digested with trypsin. After digestion, tryptic peptides were subjected to mass spectrometric analysis using two-dimensional liquid chromatography (strong cation exchange (SCX) as 1st dimension, reverse phase liquid chromatography (RPLC) as 2nd dimension) on-line interfaced with a quadrupole-orthogonal time-of-flight tandem mass spectrometer (QSTAR XL)²⁸ at UCI core facilities directed by Professor Lan Huang. The acquired spectra were submitted for automated database searching using both Mascot (<http://www.matrixsciences.com>) and Protein Prospector (<http://prospector.ucsf.edu>). Thousands of proteins are identified from the conditioned media, most of which are membrane proteins. I compared the two profiles obtained for MCF10A and MCF7 cells and identified factors that present in the medium collected from MCF10A cells but not MCF7 cells, i.e., proteins that are differentially secreted by MCF10A cells. Factors such as interleukins(IL), bone morphogenetic proteins(BMP), fibroblast growth factors(FGF), and other cytokines, are known to be involved in regulating cell proliferation and inducing cell death. We picked up six factors including BMP10, FGF11, antithrombin III (ATIII), IL1F7, IL17E and vitamin D binding protein (VBP) have been chosen as proteins of interest and subjected to further validation in the following steps.

2b) Confirmation of secreted factors by immunodepletion. Based on the cell viability curve over a week (data not shown), media collected on day 3 and 4 showed the highest cytotoxicity. I pooled media collected on day 3 and 4 for fractionation and depletion. To immunodeplete the candidate protein, pooled media were incubated with antibody against the target protein or control rabbit-against-mouse antibody for half an hour in cold room. Protein A/G agarose beads were then added to pull down the antibody-antigen complex. I performed Immunodepletion of all six factors using commercially available antibodies. To confirm the efficacy of immunodepletion, control and target protein-depleted media, as well as the immunoprecipitates, were subjected to Western blot (Figure 4). If the target protein still presented in the supernatant (ie, the media), one more cycle of depletion was performed. The depleted media was then saved for cell killing assay on MCF7 cells growing in Matrigel. Reduction of the cell killing activity after immunodepletion indicates that this depleted factor contributes to the cytotoxicity of the 10-50kDa fraction. As shown in Figure 4, depletion of each individual factor reduces the cytotoxic activity of the conditioned medium to different extents. IL17E (IL25) appears to have a relative high activity while FGF11 and BMP10 have the lowest activities which will not be included in later experiments.




Figure4. Immunoprecipitation of BMP10, FGF11, ATIII, IL1F7, IL17E, or VBP from 10-50 kDa fraction of the conditioned medium.




Figure5. Cell viability assay on MCF7 cells after 7 days of growth in 3-D culture with 10-50 kDa fraction of conditioned medium immunodepleted of FGF11, BMP10, ATIII, IL1F7, IL17E, or VBP.

2c) Reconstitution of the depleted medium by adding depleted protein back. To further confirm the requirement of a particular protein for cytotoxic activity, I will reconstitute the conditioned medium by adding the depleted protein back into the medium in which the protein is depleted by either immunodepletion or RNAi. I have already subcloned cDNAs of each candidate protein into pcDNA3.1/Hygro(+) vector for expression in mammalian cells. Human embryonic kidney fibroblast HEK293T cells were first tested for expression. But their

dependence on serum introduced considerable bovine serum albumin contamination to the later purification. Therefore, Chinese hamster ovary (CHO) cells will be used as they can be grown in serum-free medium for better purity. CHO cells will be transfected with each recombinant plasmid and stable cell clones will be selected using antibiotics hygromycin B. Each candidate protein will then be purified from medium using affinity column and further enrichment by fractionation or chromatography may be performed to provide a sufficient amount for reconstitution. If the protein is required for the cytotoxicity, reconstitution of protein should restore the cytotoxic activity of the medium depleted of a particular protein.

Tasks In Progress:

2. *Identify the secreted factors that have cytotoxic activity on breast cancer cells.*

2c) Reconstitution of the depleted medium by adding depleted protein back.

3. *Formulation of a cocktail containing the secreted factors and test of its activity on breast cancer cells in 3D culture system as well as in animals.*

3a) Quantification of each secreted factor in conditioned medium to formulate of a cocktail.

3b) Test of the cocktail in 3D gel.

3b) Test of the cocktail in animals.

Key Research Accomplishments

- We identified a cytotoxic fraction (10-50kDa) in the conditioned medium collected from MCF10A cells growing in Matrigel which can kill MCF7 cells over a 7-day continuous treatment. This cytotoxicity was confirmed on two other breast cancer cell lines, namely SKBR3 and MDA-MB468, with different genetic backgrounds.
- We found the conditioned media collected specifically on day 3 and 4 have the highest cytotoxicity. We pooled the media collected on these two days and performed mass spectrometry to identify factors within the 10-50kDa fraction.
- By comparing the profiles for MCF10A and MCF7 secreted proteins, we identified over hundreds factors that are differentially secreted by MCF10A cells but not MCF7. Among these, we decided to focus on six factors including FGF11, BMP10, ATIII, IL1F7, IL17E, and VBP.
- We performed immunodepletion of each candidate protein from the conditioned medium and cell killing assay was used to test the cytotoxicity of each immunodepleted medium. IL17E shows the highest cytotoxicity while BMP10 and FGF11 show low cytotoxicity which were then excluded from later experiments.
- The remaining four candidate proteins were expressed in CHO cells individually for purification and reconstitution of immunodepleted conditioned medium.

Reportable Outcomes

NONE

Conclusion

We identified a cytotoxic fraction (10-50kDa) from conditioned medium collected from normal mammary epithelial cells, MCF10A cells, growing in Matrigel. When this fraction was continuously fed onto breast cancer cells MCF7 cells also growing in Matrigel, MCF7 cells were killed in 7 days. This cytotoxicity was confirmed on two other breast cancer cell lines, namely SKBR3 and MDA-MB468, with different genetic backgrounds. The conditioned medium collected on day 3 and 4 have the highest cytotoxicity. From our mass spectrometry analysis on 10-50kDa fraction of the day 3 and 4 pooled conditioned medium, we identified over hundreds factors that are

differentially secreted by MCF10A cells but not MCF7 cells. We selected six genes including FGF11, BMP10, ATIII, IL1F7, IL17E, and VBP as our proteins of interests. By performing immunodepletion and cell killing assay of each candidate genes, we excluded BMP10 and FGF11. IL17E was our major interest as its immunodepleted medium showed the lowest cytotoxicity which means IL17E itself has the highest cytotoxicity on breast cancer cells. We will express the remaining four factors in CHO cells and perform reconstitution and animal experiments.

References

1. American Cancer Society (2005) Cancer Facts and Figures. Atlanta, GA:American Cancer Society.
2. Deng CX (2006) BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. *Nucleic Acids Res.* **34**:1416-1426.
3. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. *Cell* **100**:57-70.
4. Kerr JF, Wyllie AH and Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer.* **26**:239-257.
5. Kawamata H, Omotehara F, Nakashiro K, Uchida D, Hino S and Fujimori T (2003) Vesnarinone: a differentiation-inducing anti-cancer drug. *Anticancer Drugs* **14**:391-395.
6. Uhr JW, Scheuermann RH, Street NE and Vitetta ES (1997) Cancer dormancy: opportunities for new therapeutic approaches. *Nat Med.* **3**:505-509.
7. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhao L, Gu LJ and Wang ZY (1988) Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. *Blood* **72**:567-572.
8. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P and Degos L (1990) All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. *Blood* **76**:1704-1709.
9. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, et al. (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). *N. Eng. J. Med.* **324**:1385-1393.
10. Bruserud O, Gjertsen BT and Huang Ts (2000) Induction of differentiation and apoptosis- a possible strategy in the treatment of adult acute myelogenous leukemia. *Oncologist* **5**:454-462.
11. Freemantle SJ, Spinella MJ and Dmitrovsky E (2003) Retinoids in cancer therapy and chemoprevention: promise meets resistance. *Oncogene* **22**:7305-7315.
12. Dragnev KH, Petty WJ and Dmitrovsky E (2003) Retinoid targets in cancer therapy and chemoprevention. *Cancer Biol Ther.* **2**:S150-156.
13. Kawamata H, Tachibana M, Fujimori T and Imai Y (2006) Differentiation-inducing therapy for solid tumors. *Curr. Pharm. Des.* **12**:379-385.
14. Bissell MJ, Radisky D (2001) Putting tumours in context. *Nat Rev Cancer* **1**:46-54.
15. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK and Brugge JS (2002) The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. *Cell* **111**:29-40.
16. Debnath J, Muthuswamy SK and Brugge JS (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. *Methods.* **30**:256-268.
17. Furuta S, Jiang X, Gu B, Cheng E, Chen PL and Lee WH (2005) Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. *Proc Natl Acad Sci USA* **102**:9176-9181.
18. Soule HD, Vazquez J, Long A, Albert S and Brennan M (1973) A human cell line from a pleural effusion derived from a breast carcinoma. *J Natl Cancer Inst.* **51**:1409-1416.
19. Brandes LJ and Hermonat MW (1983) Receptor status and subsequent sensitivity of subclones of MCF-7 human breast cancer cells surviving exposure to diethylstilbestrol. *Cancer Res.* **43**: 2831-2835.
20. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr and Shepard HM (1985) Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. *Science* **230**:943-945.

21. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr. and Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth inhibitory potency of 123 anticancer agents. *Cancer Res.* **57**:4285-4300.
22. Xu H, Yu Y, Marciniak D, Rishi AK, Sarkar FH, Kucuk O and Majumdar AP (2005) Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. *Mol Cancer Ther.* **4**:435-442.
23. Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA, Dering J, Calzone FJ and Slamon DJ (2005) HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. *Breast Cancer Res.* **7**:1058-1079.
24. Bernard-Gallon DJ, Vissac-Sabatier C, Antoine-Vincent D, Rio PG, Maurizis JC, Fustier P, Bignon YJ (2002) Differential effects of n-3 and n-6 polyunsaturated fatty acids on BRCA1 and BRCA2 gene expression in breast cell lines. *Br. J. Nutr.* **87**:281-289.
25. Allen NP, Patel SS, Huang L, Chalkley RJ, Burlingame A, Lutzmann M, Hurt EC, and Rexach M (2002) Deciphering networks of protein interactions at the nuclear pore complex. *Mol Cell Proteomics* **1**:930-946.

Appendices

NONE